New data from the Phase 2 BRCAAway trial presented at the 2026 Genitourinary Cancers Symposium show that combining abiraterone, prednisone, and olaparib provides major benefits for patients with metastatic castration-resistant prostate cancer who carry BRCA1/2 or ATM mutations. The three-drug combination significantly outperformed either abiraterone or olaparib alone.
Patients receiving the combination had a progression-free survival of 39 months compared with 8.6 months for abiraterone alone. Median overall survival exceeded five years (68 months) with the triplet, versus 28 months for abiraterone. PSA responses were seen in 95% of patients on the combination, with 38% reaching undetectable levels, and tumor response rates were also higher than with single-agent therapy.
The results reinforce the strategy of targeting both the PARP and androgen receptor pathways at the same time rather than sequentially. Even with treatment crossover allowed, patients who started on the combination lived longer, and the regimen was generally well tolerated with few severe side effects.